PIKFYVE and cancer: Importantly, there are at least two practical implications from our study: Firstly, considering the recent interest in the clinical use of PIKfyve inhibitors, particularly for the treatment of various cancers [47, 48, 59], and given that complete intratumoral inhibition of PIKfyve or p38 MAPK activities is unlikely in vivo, combined use of PIKfyve and p38 MAPK inhibitors may prove therapeutically useful in the future.